ViaCyte Names CTO Robins as Acting CEO
ViaCyte, a San Diego preclinical cell therapy company focused on diabetes, says today the company’s chief technology officer, Allan Robins, has been named acting CEO following the departure of chief executive John West, who resigned for personal reasons. The company, which is partly funded by the California Institute for Regenerative Medicine, also promoted Kevin D’Amour to chief scientific officer. The company says West will continue with the company as a consultant and board member. Meanwhile, ViaCyte’s board has begun the search for a new CEO.